Developed Formulas
  • Promotes a balanced immune response

  • Counteracts gut dysbiosis

  • Reduces frequency and severity of asthmatic episodes

Ready to market
Clinical test
In vitro test
Hydrosoluble powder
Allergen Free
Real time stability

Lactobacilus salivarius LS01 (DSM 22775)
Bifidobacterium breve B632 (DSM 24706)

Label Claim

Food supplement with probiotic strains.

Effective nutraceutical combination

Vitamin C
EFSA claim: contributes to maintain the normal function of the immune system
Vitamin D3
EFSA claim: contributes to maintain the normal function of the immune system

Scientific Rationale

Epidemiological studies have established a strong correlation between alterations in microbial communities and an increased susceptibility to allergic airway diseases. Notably, reduced intestinal microbial diversity during infancy is linked to a heightened risk of asthma development. BIFIASTHM® is a probiotic food supplement specifically formulated to mitigate the overexpression of the type-2 immune response commonly associated with pediatric asthma. This is achieved through the synergistic combination of two probiotic strains: Lactobacillus salivarius LS01 and Bifidobacterium breve B632, each possessing unique properties:

  • LS01 and B632 can suppress the upregulated expression of Th2 cytokines, which are typically associated with asthmatic disease, and enhance the production of IL-10 [1, 2].

  • B632, known for its antipathogenic properties against coliforms and various E. coli biotypes [3]. 

In a double-blind, placebo-controlled randomized controlled trial (RCT) involving 422 children aged 3-14 years with asthma and recurrent wheezing, oral supplementation with BIFIASTHM® (8 weeks, 1 sachet twice a day followed by 8 weeks, 1 sachet per day) significantly reduced the frequency and severity of asthmatic episodes [5-9]. Notably, BIFIASTHM® treatment led to:

  • A considerable decrease in the number of subjects experiencing more than one severe asthma attack.

  • A reduction in the number of severe episodes by over half. The study population was subsequently analyzed in three different post-hoc analyses, which underscored BIFIASTHM®'s effectiveness in diminishing exacerbations and episode severity in allergic children, including both preschoolers and schoolchildren.


1. Drago L, et al. Changing of fecal flora and clinical effect of L. salivarius LS01 in adults with atopic dermatitis. J Clin Gastroenterol. 2012 Oct;46 Suppl:S56-63. doi: 10.1097/MCG.0b013e318265ef38

2. Internal Probiotical data

3. Simone M. et al. The probiotic Bifidobacterium breve B632 inhibited the growth of Enterobacteriaceae within colicky infant microbiota cultures. Biomed Res Int. 2014;2014:301053. doi: 10.1155/2014/301053.

4.Aloisio I. et al. Characterization of Bifidobacterium spp. strains for the treatment of enteric disorders in newborns. Appl Microbiol Biotechnol 2012, 96:1561–1576. Doi: 10.1007/s00253-012-4138-5

5. Drago L., et al. The Probiotics in Pediatric Asthma Management (PROPAM) Study in the Primary Care Setting: A Randomized, Controlled, Double-Blind Trial with Ligilactobacillus salivarius LS01 (DSM 22775) and Bifidobacterium breve B632 (DSM 24706). J Immunol Res. 2022 Jan 17;2022:3837418. doi: 10.1155/2022/3837418

6. Ciprandi G, et al. The Probiotics in Pediatric Asthma Management (PROPAM) study: A Post Hoc analysis in allergic children. Ann Allergy Asthma Immunol. 2022 Jul;129(1):111-113. doi: 10.1016/j.anai.2022.04.026. 

7. Ciprandi G. et al. The PRObiotics in Pediatric Asthma Management (PROPAM) study: A post hoc analysis in preschoolers. Pediatr Pulmonol. 2022 May;57(5):1355-1357. doi: 10.1002/ppul.25878

8. Drago L. et al. A post hoc analysis on the effects of a probiotic mixture on asthma exacerbation frequency in schoolchildren. ERJ Open Res. 2022 May 9;8(2):00020-2022. doi: 10.1183/23120541.00020-2022

9. Ciprandi G, et al. Probiotics in Children with Asthma. Children (Basel). 2022 Jun 29;9(7):978. doi: 10.3390/children9070978.